Get your health question answered instantly from our pool of 18000+ doctors from over 80 specialties
152 Doctors Online

By proceeding, I accept the Terms and Conditions

Dr. Andrew Rynne
MD
Dr. Andrew Rynne

Family Physician

Exp 50 years

HCM Blog Instant Access to Doctors
HCM BlogQuestions Answered
HCM Blog Satisfaction

What Is The Advantage Of Novorapid Over Actrapid?

Hi, I am Akram Our health insurance covers Actrapid but not Novorapid my privte doctor insists on Novorapid and Health insurance insists on Actrapid may be helpful and Novorapid is not a must. what is the advantages of Novorapid over Actrapid ? can NovoRapid do when Actrapid can not do? Finally, thanks for you
Mon, 4 Jul 2016
Report Abuse
Internal Medicine Specialist 's  Response
NovoRapid contains Short-acting insulin Aspart Aspart is genetically modified insulin analogues and has
full biologic activity but less tendency for self-aggregation, resulting in
more rapid absorption and onset of action and a shorter duration of
action. These characteristics are particularly advantageous for allowing
entrainment of insulin injection and action to rising plasma glucose
levels following meals. The shorter duration of action also appears to
be associated with a decreased number of hypoglycemic episodes, primarily
because the decay of insulin action corresponds to the decline
in plasma glucose after a meal. Thus, insulin aspart (novorapid) is preferred over regular insulin (Human Actrapid) for prandial coverage.
I find this answer helpful

1 Doctor agrees with this answer

Disclaimer: These answers are for your information only and not intended to replace your relationship with your treating physician.
This is a short, free answer. For a more detailed, immediate answer, try our premium service [Sample answer]
Share on
 

Related questions you may be interested in


Loading Online Doctors....
What Is The Advantage Of Novorapid Over Actrapid?

NovoRapid contains Short-acting insulin Aspart Aspart is genetically modified insulin analogues and has full biologic activity but less tendency for self-aggregation, resulting in more rapid absorption and onset of action and a shorter duration of action. These characteristics are particularly advantageous for allowing entrainment of insulin injection and action to rising plasma glucose levels following meals. The shorter duration of action also appears to be associated with a decreased number of hypoglycemic episodes, primarily because the decay of insulin action corresponds to the decline in plasma glucose after a meal. Thus, insulin aspart (novorapid) is preferred over regular insulin (Human Actrapid) for prandial coverage.